中国临床药理学杂志2025，Vol.41Issue(8)：1164-1169,6.DOI:10.13699/j.cnki.1001-6821.2025.08.020
SGLT-2抑制药治疗2型糖尿病的有效性分析
Evaluation of SGLT-2 inhibitors for type 2 diabetes mellitus treatment effectiveness
摘要
Abstract
Objective To establish a pharmacodynamic model of sodium-glucose transporter 2 inhibitors(SGLT-2i)in order to evaluate the efficacy characteristics of the drugs.Methods A model-based meta-analysis was used.By searching randomized controlled trials of SGLT-2i monotherapy in patients with type 2 diabetes(T2DM)in databases,the change in glycosylated hemoglobin(HbA1c)from baseline was used as the efficacy indicator.The pharmacodynamic models of SGLT-2i and placebo were constructed,and the covariates were screened to determine the factors affecting the drug's efficacy.Results A total of 39 studies were included,involving 96 trial groups,8 534 participants,and 13 drugs(dapagliflozin,canagliflozin,empagliflozin,ipragliflozin,luseogliflozin,ertuglilfozin,enavogliflozin,henagliflozin,licogliflozin,sotagliflozin,bexagliflozin,janagliflozin and tofogliflozin).The time-effect relationships of the drug group and the placebo group were consistent with the Emax model,and fasting plasma glucose baseline had an effect on the pharmacodynamic parameters of SGLT-2i.Conclusion The final model can describe the pharmacodynamic characteristics of the drug and placebo groups,and there is a significant association between FPB baseline and drug efficacy.关键词
钠-葡萄糖协同转运蛋白-2抑制药/基于模型的荟萃分析/2型糖尿病/糖化血红蛋白/药效学模型Key words
sodium-glucose transporter-2 inhibitor/model-based meta-analysis/type 2 diabetes/hemoglobin A1c/pharmacodynamic model分类
医药卫生引用本文复制引用
马昕怡,谢潘潘,陈志兴,翁茜,史爱欣..SGLT-2抑制药治疗2型糖尿病的有效性分析[J].中国临床药理学杂志,2025,41(8):1164-1169,6.基金项目
首都卫生发展科研专项基金资助项目(首发2022-2Z-4056) （首发2022-2Z-4056）
